Disclosures for "Efficacy and Safety of TAK-861, an Oral Orexin Receptor 2 Agonist, in Individuals with Narcolepsy Type 1: Results from a Phase 2 Trial and Long-Term Extension Study Interim Analysis"
-
Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for idorsia. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avadel.
-
Dr. Mignot has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Mignot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceutical. Dr. Mignot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals, Inc. . Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for EcoR1. Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for ApneaCo. Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Mignot has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Centessa .
-
The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TAKEDA. The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOPROJET. The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. The institution of Dr. Plazzi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for OREXIA. The institution of Dr. Plazzi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for OREXIA/CENTESSA.
-
The institution of Dr. Lammers has received research support from Takeda.
-
Dr. Kadali has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Dr. Kadali has stock in Takeda Pharmaceuticals.
-
Dr. Stukalin has received personal compensation for serving as an employee of Takeda. Dr. Stukalin has stock in Takeda.
-
Dr. Hang has received personal compensation for serving as an employee of Takeda.
-
Yeting Du has received personal compensation for serving as an employee of Takeda Pharmaceuticals.
-
Dr. Abraham has received personal compensation for serving as an employee of Takeda Pharmaceutical Company. Dr. Abraham has stock in Takeda.
-
Dr. Von Rosenstiel has received personal compensation for serving as an employee of Takeda. Dr. Von Rosenstiel has stock in Takeda.
-
Mr. Tanaka has received personal compensation for serving as an employee of Takeda.
-
Ms. Naylor has received personal compensation for serving as an employee of Takeda. Ms. Naylor has stock in Takeda.
-
Dr. Cai has received personal compensation for serving as an employee of Takeda.
-
Dr. Olsson has received personal compensation for serving as an employee of Takeda. Dr. Olsson has stock in Takeda.